Koers Daiichi Sankyo Company, Limited Other OTC
Aandelen
DSNKY
US23381D1028
Farmaceutische producten
Omzet 2024 | 1.602 mld. 10,11 mld. 9,46 mld. | Omzet 2025 * | 1.761 mld. 11,12 mld. 10,4 mld. | Marktkapitalisatie | 9.607 mld. 60,65 mld. 56,74 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 | 201 mld. 1,27 mld. 1,19 mld. | Nettowinst (verlies) 2025 * | 186 mld. 1,17 mld. 1,1 mld. | EV/omzet 2024 | 5,72 x |
Nettoliquiditeiten 2024 * | 556 mld. 3,51 mld. 3,28 mld. | Nettoliquiditeiten 2025 * | 455 mld. 2,87 mld. 2,69 mld. | EV/omzet 2025 * | 5,2 x |
K/w-verhouding 2024 |
45,6
x | K/w-verhouding 2025 * |
49
x | Werknemers | - |
Dividendrendement 2024 |
1,05% | Dividendrendement 2025 * |
1,14% | Vrij verhandelbaar | 97,04% |
Recentste transcriptie over Daiichi Sankyo Company, Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01-04-07 |
Hiroyuki Okuzawa
PSD | President | 61 | 01-04-17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 01-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 01-06-19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 01-06-19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01-04-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |